Last edition
News about "Transthyretin-mediated amyloid cardiomyopathy"
AstraZeneca, Ionis' Wainua Misses Phase 3 Primary Endpoint in ATTR-CM Trial
AstraZeneca and Ionis reported that Wainua (eplontersen) missed the primary endpoint in the phase 3 CARDIO-TTRansform trial for ATTR-CM, while maintaining a consistent safety profile.
Transthyretin-mediated Amyloid Cardiomyopathy | 10/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members